WO2007084986A2 - Compositions and methods for preventing or treating feline chronic kidney disease - Google Patents
Compositions and methods for preventing or treating feline chronic kidney disease Download PDFInfo
- Publication number
- WO2007084986A2 WO2007084986A2 PCT/US2007/060773 US2007060773W WO2007084986A2 WO 2007084986 A2 WO2007084986 A2 WO 2007084986A2 US 2007060773 W US2007060773 W US 2007060773W WO 2007084986 A2 WO2007084986 A2 WO 2007084986A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- protein
- feline
- dry matter
- kidney disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 320
- 241000282324 Felis Species 0.000 title claims abstract description 256
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 209
- 238000000034 method Methods 0.000 title claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 206
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 206
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims abstract description 90
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 235000013305 food Nutrition 0.000 claims description 54
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 42
- 241000282326 Felis catus Species 0.000 claims description 41
- 239000004615 ingredient Substances 0.000 claims description 38
- 229910052698 phosphorus Inorganic materials 0.000 claims description 38
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 37
- 239000011574 phosphorus Substances 0.000 claims description 37
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 29
- 229910052708 sodium Inorganic materials 0.000 claims description 29
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 28
- 239000011591 potassium Substances 0.000 claims description 28
- 229910052700 potassium Inorganic materials 0.000 claims description 28
- 239000011734 sodium Substances 0.000 claims description 28
- 229940109239 creatinine Drugs 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 9
- 230000000007 visual effect Effects 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 208000017169 kidney disease Diseases 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 172
- 150000001875 compounds Chemical class 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 230000003907 kidney function Effects 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 108010068370 Glutens Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000021312 gluten Nutrition 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000019764 Soybean Meal Nutrition 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 235000015277 pork Nutrition 0.000 description 5
- 239000004455 soybean meal Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108010070551 Meat Proteins Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108010084695 Pea Proteins Proteins 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- -1 e.g. Chemical compound 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000019702 pea protein Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000021023 sodium intake Nutrition 0.000 description 2
- 229940071440 soy protein isolate Drugs 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 229940063711 lasix Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 229940080693 reglan Drugs 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/22—Compounds of alkali metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/26—Compounds containing phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Definitions
- the invention relates generally to compositions for preventing or treating chronic kidney disease and particularly to compositions for preventing or treating feline chronic kidney disease.
- the kidneys have five primary functions. They filter waste products from the body (e.g.. urea and creatinine), regulate electrolytes (e.g., potassium, calcium, phosphorus, and sodium), produce erythropoietin (which stimulates bone marrow to produce red blood cells), produce rennin (which controls blood pressure), and produce and concentrate urine.
- electrolytes e.g., potassium, calcium, phosphorus, and sodium
- erythropoietin which stimulates bone marrow to produce red blood cells
- produce rennin which controls blood pressure
- Chronic kidney disease e.g., chronic renal failure
- the kidneys have a large built-in reserve as only approximately 30% of kidney capacity is needed for normal kidney function.
- Kidney capacity diminishes with time for a variety of reasons, for example, advanced age and diseases and medications that damage the kidney(s).
- Renal insufficiency is characterized by decrease in renal function, and is generally observed when about 70% of kidney function has been lost (i.e.. when only about 30% of kidney capacity is available).
- Clinical signs are typically not obvious during the phases of loss of renal reserve and renal insufficiency, thereby making it difficult to detect CKD.
- Azotemia the third phase of CKD, is characterized by an abnormally high concentration of urea, creatinine, and/or other non-protein nitrogen-containing substances in the blood. Renal function is markedly reduced in the azotemic phase, although clinical signs may be mild and can go undetected.
- Uremia is characterized by the presence of abnormal quantities of urine or urine constituents in blood.
- the uremic phase is characterized by overt clinical signs
- One object of the invention Io provide compositions suitable for preventing CKD in felines.
- compositions suitable for treating CKD in felines It is another object to provide compositions suitable for treating CKD in felines.
- One or more of these and other objects are achieved by preventing chronic feline kidney disease by feeding the feline a composition comprising from about 33 to about 38%. or from about 28 to about 35% protein on a dry matter basis and treating chronic feline kidney disease by feeding the feline a composition that comprises from about 26 to about 30%, from about 28 to about 30%, or from about 33 to about 35% protein on a dry matter basis, wherein the protein comprises at least about 75% vegetable protein.
- the present invention provides a method for preventing CKD in a feline susceptible to developing CKD.
- the method comprises feeding the feline a composition comprising from about 33 to about 38%, or from about 28 to about 35% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition that comprises from about 33 to about 35%. or from about 28 to about 31% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition that comprises from about 33 to about 34%, or from about 28 to about 30% protein.
- the method comprises feeding the feline a composition that comprises from about 34 to about 35%, or from about 29 to about 31 % protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the method comprises feeding the feline a composition that comprises from about 28 or about 28.5 to about 29. about 29.5, about 30, about 30.5, or about 3 1 % protein wherein the protein comprises at least about 75. at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the method comprises feeding the feline a composition that comprises from about 33 or about 33.5 to about 34.
- the method comprises feeding the feline a composition selected from the compositions of the invention for preventing renal insufficiency.
- a composition selected from the compositions of the invention for preventing renal insufficiency.
- One skilled in the art would understand that either a single composition of the invention can be fed to the feline or. alternatively, different such compositions can be fed to the feline for varying time intervals.
- lhe method comprises feeding the feline a composition comprising from about 31 to about 35%, or from about 35 to about 38% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 32 to about 34%, or from about 36 to about 37% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 32 to about 35%, or from about 36 to about 38% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 33 to about 35%, or from about 36.5 to about 38% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 31 , about 32, or about 33 to about 34 or about 35% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 35. about 36, or about 36.5 to about 37 or about 38% protein wherein the protein comprises at least about 75, at least about 80, at least about 85%, at least about 90. or at least about 95% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 31 to about 32, about 33. about 34, or about 35% protein wherein the protein comprises at least about 75, at least about 80. at least about 85, at least about 90, or at least about 95% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 35 to about 36, about 36.5, about 37, or about 38% protein wherein the protein comprises at least about 75, at least about 80. at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition that is fed to the feline further comprises from about 0.45 to about 0.8%. or from 0.51 to about 0.70% phosphorus on a dry matter basis.
- the composition that is fed to the feline comprises from about 0.45 to about 0.6%, or from about .51 to about .65% phosphorus, for example, from about 0.45 to about 0.55%. from about 0.45 to about 0.5% phosphorus, from about 0.51 to about 0.60% or from about 0.5! to about 0.55% phosphorus.
- the composition fed to the feline comprises from about 0.6 to about 0.8% phosphorus, for example, from about 0.7 to about 0.8% or from about 0.6 or 0.65 to about 0.75% phosphorus.
- the composition that is fed to the feline further comprises from about 0.2 or 0.25 to about 0.40%, or from about 0.2 to about 0.35% sodium on a dry matter basis. In some such embodiments, the composition fed to the feline comprises from about 0.2 to about 0.35% sodium, and in other such embodiments, the composition fed to the feline comprises from about 0.2 to about 0.25% sodium.
- the composition that is fed to the feline further comprises from about 0.75 to about 1 % potassium on a dry matter basis.
- the composition fed to the feline comprises from about 0.8 to about 1 % potassium, and in other such embodiments, the composition comprises from about 0.75 to about 0.9% potassium.
- the composition fed to the feline further comprises two or more of phosphorus, sodium, and potassium in any combination of the amounts discussed above.
- the present invention provides a method for treating CKD in a feline.
- the method comprises feeding the feline a composition comprising from about 26 to about 30%. or about 28 to about 30% protein on a dry matter basis wherein the protein present in the composition comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 26 to about 27%. or from about 28 to about 29% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 27 or 29 to about 30% protein wherein the protein comprises at least about 75% vegetable protein.
- the method comprises feeding the feline a composition comprising from about 28 or about 28.5 to about 29, about 29.5, or about 30% protein wherein (he protein comprises at least about 75. at least about 80. at least about 85, at least about 90. or at least about 95% vegetable protein.
- the composition comprises from about 26 or about 27 to about 28, about 29, or about 30% protein wherein the protein comprises at least about 75, at least about 80. at least about 85, at least about 90, or at least about 95% vegetable protein.
- the method comprises feeding the feline a composition selected from the compositions of the invention for treating CKD.
- CKD a single composition of the invention can be fed to the feline or.
- the composition that is fed to the feline further comprises from about 0.20 to about 0.50%. or from about 0.45 to about 0.6% phosphorus on a dry matter basis.
- the composition fed to the feline comprises from about 0.20 to about .045%, or from about 0.45 to about 0.55% phosphorus.
- the composition fed to the feline comprises from about 0.20 to about 0.40%, or from about 0.45 to about 0.5% phosphorus.
- the composition that is fed to the feline further comprises from about 0.2 to about 0.25%. or from about 0.23 to about 0.30% sodium on a dry matter basis.
- the composition that is fed to the feline further comprises from about 0.75 to about 1 % potassium on a dry matter basis. In some such embodiments, the composition that is fed to the feline comprises from about 0.7 to about 0.9% potassium. In other such embodiments, the composition fed to the feline comprises from about 0.75 to about 0.85% potassium.
- the composition fed to the feline further comprises two or more of phosphorus, sodium, and potassium in any combination of the amounts discussed above.
- the methods of the invention for prevention and treatment of CKD further comprise administering to the feline an anti-CKD agent.
- An anti-CKD agent is a compound, a derivative thereof (e.g.. a salt, solvate, or hydrate of the compound), or a composition comprising such compounds and/or derivatives that is used to prevent and/or treat CKD.
- Such an agent is administered in conjunction with feeding a composition of the invention.
- the term "in conjunction" means that an agent is administered to the feline either together with a composition of the present invention or separately from the composition at the same or different frequency via the same or different administration route and either at about the same time as the composition or periodically.
- Administering means that the agent is introduced in a suitable dosage form into the feline by a suitable administration route, for example, orally, topically, or parcnterally.
- “About at the same time” generally means that an agent is administered when a composition of the invention is fed to the feline or within about 72 hours of feeding the composition to the feline.
- '"Periodically generally means that an agent is administered to a feline following a dosage schedule suitable for administering the agent while composition of the invention is fed to the feline routinely as appropriate for that feline.
- the term "in conjunction" specifically includes situations when an agent is administered to a feline for a prescribed period of time while a composition of the invention is fed to the feline for a much longer period of time (e.g., for life). If more than one agent is administered, the dosage form and route of administration for each agent may vary. In addition, one composition of the invention may be substituted with another composition of the invention while a specific agent is administered to the feline.
- Suitable anti-CKD agents include, for example, agents that reduce blood pressure, e.g., calcium channel blockers (e.g.. amlodipine besylate) or protein loss in urine.
- ACE-inhibitors e.g.. benazepril
- antibiotics agents that treat anemia, e.g., feline recombinant erythropoietin, diuretics, e.g., lasix furoesemide
- agents that control vomiting e.g., anti-emetics (e.g., REGLAN®)
- Such agents can be administered, for example, in the form of salts derived from inorganic or organic acids.
- a salt of the compound may be advantageous due to one or more of the salt's physical properties, for example, enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil.
- the salt preferably is a pharmaceutically-acceptable salt.
- the total daily dose of an anti-CKD agent is typically from about 0.001 to about 100 mg/kg, preferably from about 0.001 to about 30 mg/kg, and even more preferably from about 0.01 to about 10 mg/kg body weight. Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the anti-CKD agent will be repeated a plurality of times. Multiple doses per day typically may be used to increase the total daily dose.
- Factors affecting the preferred dosage regimen include, for example, the age, weight, and condition of the feline; the severity of the disease; the route of administration; pharmacological considerations (e.g., activity, efficacy, and pharmacokinetic and toxicology profiles of the particular anti-CKD agent); whether a drug delivery system is utilized; and whether the anti-CKD agent is administered as part of a drug combination.
- the dosage regimen actually employed can vary widely, and can differ from the dosage regimen set forth above.
- the invention provides a composition suitable for preventing CKD in a feline susceptible to developing renal insufficiency.
- the composition comprises from about from about 33 to about 38%, or 28 to about 35% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein.
- CKD is a terminal disease in felines, it is important to prevent a decrease in renal function in a feline that does not shows clinical signs of CKD.
- a feline is one which has not been diagnosed with CKD. but is at risk to develop CKD due to. for example, advanced age, genetic predisposition, or disease(s) or medication(s) that can damage the feline's kidney(s).
- Preventing CKD includes reducing the risk of. delaying the onset of, and/or keeping a feline from developing CKD.
- feeding a composition of the invention for preventing CKD can reduce a feline's risk of developing CKD.
- the feline is a companion feline.
- a companion feline can be a feline kept as a pet.
- a companion feline can also be a feline from a widely domesticated species, for example, cats (Felis domesticns) regardless of whether or not it is kept as a pet.
- the feline is an adult feline.
- An adult feline is a feline of any age after juvenile growth and development has been completed, including senior and geriatric felines.
- an adult cat typically is one that is from about one year old through the remainder of its life.
- a senior feline is one of an age at which it is at a risk for suffering from an age-related disease regardless of whether or not the feline shows obvious physical or behavioral signs of aging.
- a senior cat typically is a cat from about seven to about eleven years old.
- a geriatric feline is a feline showing signs of aging.
- a geriatric cat typically is a cat of about twelve years of age and beyond.
- the composition for preventing CKD in a feline comprises from about 33 to about 38%, or from about 28 to about 35% protein.
- Commercial adult cat foods typically comprise from about 35 to about 45% protein on a dry matter basis.
- a composition of the invention for preventing CKD may comprise less protein than most commercially available adult cat foods.
- the composition for preventing CKD comprises from about 28 to about 31 %, or from about 33 to about 38% protein on a dry matter basis.
- the composition comprises from about 28 to about 30%, or from about 33 to about 34% protein; and in other such embodiments, the composition comprises from about 29 to about 31 % protein, or from about 33.5 to about 35% protein. .
- the composition comprises from about 28 or about 28.5 to about 29, about 29.5, about 30, about 30.5. or about 31 % protein. In another embodiment, the composition comprises from about 33 or about 33.5 to about 34, about 34.5. or about 35% protein.
- the composition for preventing CKD comprises from about 31 to about 35%. or from about 35 to about 38% protein.
- the composition comprises from about 32 to about 34% protein, or from about 36 to about 37% protein.
- the composition comprises from about 32 to about 35% protein, or from about 36 to about 38% protein.
- the composition comprises from about 33 to about 35%. or from about 34 to about 38% protein.
- the composition comprises from about 31, about 32, or about 33 (o about 34 or about 35% protein.
- !bc composition comprises from about 35. about 36, or about 36.5 to about 37 or 38% protein.
- the composition comprises from about 31 to about 32, about 33, about 34. or about 35% protein. In another embodiment, lhe composition comprises from about 35 to about 36. 37, or about 38% protein. 10036] Dietary protein restriction is beneficial for preventing and treating CKD. Excessive protein is catabolized to urea and other nitrogenous compounds normally excreted by the kidneys. Decreased renal function leads to accumulation of these compounds. On the other hand, endogenous proteins will be degraded if amino acid intake is insufficient to maintain nitrogen balance. Thus, a composition of the invention for preventing and/or treating CKD can facilitate achieving nitrogen balance, and can help limit the accumulation of waste products by decreasing protein intake.
- the protein in a composition of the present invention for preventing CKD comprises at least about 75% vegetable protein (i.e.. a composition of the invention for preventing CKD comprises from about 33 to about 38%, or from about 28 to about 35% protein wherein the protein present in the composition comprises at least about 75% vegetable protein). In some such embodiments, the composition comprises at least about 80% vegetable protein.
- the composition comprises at least about 85% vegetable protein.
- the protein comprises at least about 90% vegetable protein.
- the protein comprises at least about 95% vegetable protein (i.e., from at least about 95 up to about 100% vegetable protein).
- the composition for preventing CKD comprises from about 28 to about 31% protein wherein the protein comprises at least about 75% vegetable protein.
- the composition comprises from about 26 to about 30%. or from about 28 to about 30% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90. or at least about 95% vegetable protein.
- the composition comprises from about 29 to about 31 % protein wherein the protein comprises at least about 75, at least about 80. at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 28 or about 28.5 to about 29, about 29.5. about 30, about 30.5, or about 31 % protein wherein the protein comprises at least about 75. at least about 80, at least about 85. at least about 90. or at least about 95% vegetable protein.
- the composition for preventing CKD comprises from about 31 to about 35% protein wherein the protein comprises at least about 75% vegetable protein.
- the composition comprises from about 31. about 32. or about 33 to about 34 or about 35% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 31 to about 32. about 33, about 34, or about 35% protein, wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 28 or about 28.5 to about 29, about 29.5, or about 30% protein, wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90. or at least about 95% vegetable protein.
- vegetable protein suitable for preparing compositions of the invention include, but are not limited to, potato concentrate, soy concentrate, soy protein isolate, soybean meal, corn gluten meal, rice protein isolate, pea protein concentrate, wheat protein concentrate, and wheat protein isolate.
- Vegetable protein may be isolated from any portion of a plant, isolated from more than one portion of a plant, and isolated from more than one plant by methods known by those of skill in the art. Vegetable protein may also be concentrated by methods known by those of skill in the art.
- the composition of the invention for preventing CKD in a feline further comprises from about 0.45 to about 0.8%, from 0.51 to about 0.80%, or from about 0.51 to about 0.70% phosphorus on a dry matter basis.
- the composition comprises about 0.45 to about 0.6% phosphorus or from about 0.51 to about 0.65%, for example, from about 0.45 to about 0.55% or from about 0.45 to about 0.5% phosphorus, or from about 0.51 to about 0.60 or from about 0.51 to about 0.55% phosphorus.
- the composition comprises from about 0.6 or about 0.65 to about 0.8% phosphorus, for example, from about 0.7 to about 0.8% or from about 0.6 or 0.65 to about 0.75% phosphorus.
- phosphorus' ' means the phosphorus atom without reference to its molecular or ionic form.
- the composition of the invention for preventing CKD in a feline further comprises from about 0.20 or 0.25 to about 0.40%. or from about 0.2 to about 0.35% sodium on a dry matter basis. In some such embodiments, the composition comprises from about 0.2 to about 0.25 or 0.30% sodium. In other such embodiments, the composition comprises from about 0.25 to about 0.3 or 0.35% sodium.
- sodium means the sodium atom without reference to its molecular or ionic form.
- the composition of the invention for preventing CKD in a feline further comprises from about 0.75 to about 1% potassium on a dry matter basis. In some such embodiments, the composition comprises from about 0.8 to about 1 % potassium. In other such embodiments, the composition comprises from about 0.75 to about 0.9% potassium.
- the term "potassium " ' means the potassium atom without reference to its molecular or ionic form.
- composition of the invention for preventing CKD further comprises any two or more of phosphorus, sodium, and potassium in any combination of the amounts discussed above.
- the invention provides a composition suitable for treating CKD in a feline.
- the composition comprises from about 26 to about 30%, or about 28 to about 30% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein.
- Treatment can help a feline with CKD to live a healthier, longer, and more active life.
- Treating CKD includes ameliorating and or suppressing CKD, which may include, e.g., slowing the decrease in renal function or decrease in glomerular filtration rate of an animal.
- CKD CKD
- blood and urine tests as well as, for example, radiography, ultrasound, renal biopsy, and/or palpation.
- felines with CKD typically have an elevated serum creatinine and/or BUN.
- a composition for treating CKD of the invention is suitable for any feline with CKD. Examples of felines that can be treated with a composition of the invention are discussed above in the context of the compositions of the invention for preventing CKD.
- the composition comprises from about 28 to about 29% protein, and in other such embodiments, the composition comprises from about 29 to about 30% protein. In yet other such embodiments, the composition comprises from about 28 or about 28.5 to about 29. about 29.5, or about 30% protein,
- the protein in the composition for treating CKD comprises at least about 75% vegetable protein (i.e.. a composition of the present invention for treating CKD in a feline comprises from about 26 to about 30%, or from about 28 to about 30% protein wherein the protein comprises at least about 75% vegetable protein).
- the composition comprises at least about 80% vegetable protein. In other such embodiments, the composition comprises at least about 85% vegetable protein. In other such embodiments, the protein comprises at least about 90% vegetable protein.
- the protein comprises at least about 95% vegetable protein (i.e.. from at least about 95 up to about 100% vegetable protein).
- the composition for treating CKD in a feline comprises from about 28 or about 28.5 to about 29, about 29.5, or about 30% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition for treating CKD further comprises from about 0.20 to about 0.50%, or from about 0.45 to about 0.6% phosphorus on a dry matter basis. In some such embodiments, the composition comprises from about 0.20 to about 0.45, or from about 0.45 to about 0.55% phosphorus; and in other such embodiments from about 0.20 to about 0.40, or from about 0.45 to about 0.5% phosphorus.
- the composition for treating CKD further comprises from about 0.2 to about 0.25%. or from about 0.23 to about 0.30% sodium on a dry matter basis. [0050
- the composition for treating CKD further comprises any two or more of phosphorus, sodium, and potassium in any combination of the amounts discussed above.
- the compositions of the invention for preventing and/or treating CKD comprise a food composition (i.e., the compositions comprise one or more food compositions of the present invention).
- the compositions meet or are below the AAFCO's minimum nutrient level requirements for reproduction or maintenance. It is understood by those of skill in the art that compositions affecting CKD may be below AAFCO recommendations for phosphorus and protein levels.
- the food compositions comprise a dry food.
- the food compositions comprise a semi-moist food.
- the food compositions comprise a moist food.
- the food compositions comprise a treat, snack, supplement, or partially or fully edible toy.
- the compositions comprise a mixture of one or more foods.
- the invention provides a kit comprising a composition of the invention.
- the kit is suitable for preventing and/or treating CKD in a feline.
- the kit further comprises an anti-CKD agent (i.e., one or more anti-CKD agents).
- the kit further comprises instructions for one or more of (1) feeding the composition to a feline, (2) administering an anti-CKD agent to the feline in conjunction with feeding the feline the composition.
- the kit comprises two or more ingredients that, when combined together and optionally with additional ingredients that are or are not a part of the kit, yield a composition of the present invention. If such additional ingredients are to be used, the kit provides instructions about these ingredients. In some embodiments, the kit further comprises an anti-CKD agent.
- the kit further comprises instructions for one or more of ( 1 ) preparing a composition of the invention for preventing CKD in a feline by combining the ingredients. (2) preparing a composition of the invention for treating CKD in a feline by combining the ingredients,
- the kit comprises in separate containers in a single package or in separate containers in a virtual package, as appropriate for the kit component, a composition of the invention or two or more ingredients, that, when combined together and optionally with additional ingredients that are or are not a part of the kit. yield a composition of the invention, and instructions for one or more of ( 1 ) preparing a composition of the invention for preventing CKD in a feline by combining the ingredients, (2) preparing a composition of the invention for treating CKD in a feline by combining the ingredients, (3) feeding a feline a composition of the invention Io prevent CKD,
- treating CKD in a feline by feeding the feline a composition of the invention for treating CKD, (9) preventing CKD in a feline by administering to the feline an anti-CKD agent in conjunction with feeding the feline a composition of the invention for preventing CKD, and (10) treating CKD in a feline by administering to the feline an anti-CKD agent in conjunction with feeding the feline a composition of the invention for treating CKD.
- the term "single package” 1 generally means that the components of a kit are physically associated in or with one or more containers and considered as a unit of manufacture, distribution, sale, or use.
- Containers include, for example, bags, boxes, bottles, shrink wrap packages, stapled or otherwise fixed components, and combinations thereof.
- a single package can be, for example, containers or individual food compositions physically associated such that they are considered a unit for manufacture, distribution, sale, or use.
- the term '"virtual package” generally means that the components of a kit are associated by directions on one or more physical or virtual kit components instructing the user how to obtain additional components, e.g., in a bag containing one component and directions instructing the user to go to a website, contact a recorded message, view a visual message, or contact a caregiver to obtain instructions on how to use the kit.
- the kit comprises a virtual package
- the kit is limited to instructions in a virtual environment with one or more physical kit components.
- the kit is suitable for preventing chronic kidney disease in a feline and comprises in separate containers in a single package or in separate containers in a virtual package, as appropriate, a composition that comprises from about 33 to about 38%, or from about 28 to about 35% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein, or two or more ingredients that, when combined together and. optionally, with additional ingredients that are or are not a part of the kit, yield a composition that comprises from about 33 to about 38%, or from about 28 to about 35% protein wherein the protein comprises at least about 75% vegetable protein, and one or more of ( 1 ) an anti-chronic kidney disease agent, (2) instructions for preparing the composition, (3) instructions for feeding the composition to a feline.
- a composition that comprises from about 33 to about 38%, or from about 28 to about 35% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein, or two or more ingredients that, when combined together and. optionally, with additional ingredients that are or are not a part of the
- the kit comprises a composition that comprises from about 31 to about 35% protein, or two or more ingredients that, when combined together and, optionally, with additional ingredients that arc or are not a part of the kit, yield a composition that comprises from about 31 to about 35% protein.
- the kit is suitable for treating chronic kidney disease in a feline and comprises in separate containers in a single package or in separate containers in a virtual package, as appropriate, a composition that comprises from about 26 to about 30%. or from about 28 to about 30% protein wherein the protein comprises at least about 75% vegetable protein, or two or more ingredients that, when combined together and, optionally, with additional ingredients that are or are not a part of the kit, yield a composition that comprises from about 26 to about 30%. or from about 28 to about 30% protein wherein the protein comprises at least about 75% vegetable protein, and one or more of (1 ) an anti-chronic kidney disease agent.
- the invention provides a means for communicating information about or instructions for one or more of (1) feeding a feline a composition of the invention to prevent CKD, (2) feeding a feline a composition of the invention to treat CKD, (3) administering an anti-CKD agent to a feline in conjunction with feeding the feline a composition of the invention to prevent CKD, (4) administering an anti-CKD agent to a feline in conjunction with feeding the feline a composition of the invention to treat CKD.
- preventing CKD in a feline by feeding the feline a composition of the invention for preventing CKD (6) treating CKD in a feline by feeding the feline a composition of the invention for treating CKD, (7) preventing CKD in a feline by administering to the feline an anti-CKD agent in conjunction with feeding the feline a composition of the invention for preventing CKD, (8) treating CKD in a feline by administering to the feline an anti-CKD agent in conjunction with feeding the feline a composition of the invention for treating CKD, (9) using a kit of the Invention to prevent CKD, and (10) using a kit of the invention to treat CKD.
- the communication means comprise, for example, a document, digital storage media, optical storage media, audio presentation, or visual display containing the information or instructions.
- the communication means is a displayed web site or a brochure, product label, package insert, advertisement, or visual display containing such information or instructions.
- Useful information or instructions include, for example, (I) information and instructions how to use a composition, method, or kit of the invention and (2) contact information for animal caregivers if they have a question about the invention and its uses.
- the present invention provides a means for communicating information about or instructions for one or more of (I) preventing chronic kidney disease in a feline by feeding the feline a composition of the invention that comprises from about 33 to about 38%, or from about 28 to about 35% protein wherein the protein comprises at least about 75% vegetable protein, (2) preventing chronic kidney disease in a feline by administering to the feline an anti- chronic kidney disease agent in conjunction with feeding the feline a composition of the invention that comprises from about 33 to about 38%, or from about 28 to about 35% protein wherein the protein comprises at least about 75% vegetable protein, and (3) using a kit of the invention for preventing CKD in a feline that comprises a composition comprising from about 33 to about 38%, or from about 28 to about 35% protein wherein the protein comprises at least about 75% vegetable protein or two or more ingredients that, when combined together and, optionally, with additional ingredients, yield a composition that comprises from about 33 to about 38%, or from about 28 to about 35% protein wherein the
- the present invention provides a means for communicating information about or instructions for one or more of (1) treating chronic kidney disease in a feline by feeding the feline a composition of the invention that comprises from about 26 to about 30%, or from about 28 to about 30% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein, (2) treating chronic kidney disease in a feline by administering to the feline an anti-chronic kidney disease agent in conjunction with feeding the feline a composition of the invention that comprises from about 26 to about 30%, or From about 28 to about 30% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein, and (3) using a kit of the invention for treating CKD in a feline that comprises a composition comprising from about 26 to about 30%, or from about 28 to about 30% protein wherein the protein comprises at least about 75% vegetable protein or two or more ingredients that, when combined together and, optionally, with additional ingredients,
- the invention provides for a use of a composition of the invention to prepare a medicament suitable for preventing feline CKD.
- the composition generally comprises from about 33 to about 38%. or from about 28 to about 35% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein.
- the composition comprises from about 33 to about 35%. or from about 28 to about 31 % protein wherein the protein present in the composition comprises at least about 75% vegetable protein.
- the composition comprises from about 33 to about 34%, or from about 26 to about 30%, or from about 28 to about 30% protein wherein the protein comprises at least about 75. at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 34 to about 35%. or from about 29 to about 31 % protein wherein the protein comprises at least about 75, at least about 80. at least about 85. at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 28 or about 28.5 to about 29, about 29.5, about 30, about 30.5, or about 31% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 33 or about 33.5 to about 34, about 34.5, or about 35% proiein wherein lhe proiein comprises at least about 75, at least about 80. at least about 90. or at least about 95% vegetable protein.
- the composition comprises from about 31 to about 35% protein wherein the protein comprises at least about 75% vegetable protein. In some such embodiments, the composition comprises from about 31 , about 32, or about 33 to about 34 or about 35% protein wherein the protein comprises at least about 75. at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein. In another embodiment, the composition comprises from about 35, about 36, or about 36.5 to about 37 or about 38% protein wherein the protein comprises at least about 75. at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein. In other such embodiments, the composition comprises from about 31 to about 32. about 33, about 34.
- composition further comprises one or more of sodium, phosphorus, and potassium in the amounts discussed above.
- the composition comprises from about 35 to about 36. about 36.5, about 37, or about 38% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises a food composition.
- the invention provides for a use of a composition of the invention to prepare a medicament suitable for treating feline CKD.
- the composition generally comprises from about 26 to about 30%, or from about 28 to about 30% protein on a dry matter basis wherein the protein comprises at least about 75% vegetable protein.
- the composition comprises from about 28 or about 28.5 to about 29, about 29.5, or about 30% protein wherein the protein comprises at least about 75. at least about 80. at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition comprises from about 26 or about 27 to about 28, about 29, or about 30% protein wherein the protein comprises at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95% vegetable protein.
- the composition further comprises one or more of phosphorus, sodium, and potassium in the amounts discussed above.
- the composition comprises a food composition.
- medicaments are prepared by admixing a compound or composition with excipients, buffers, binders, plasticizers, colorants, diluents, compressing agents, lubricants, flavorants. moistening agents, and other ingredients known to skilled artisans to be useful for producing medicaments and formulating medicaments that are suitable for administration to a feline.
- the invention provides methods for preparing compositions of the invention for preventing and/or treating CKD.
- Such composition can be prepared, for example, by mixing various ingredients (including food compositions) that, when combined, yield a composition of the invention.
- Compositions of the invention can also be prepared by the methods discussed in, for example, Small Animal Nutrition, pages 127-146 (2000).
- plant ingredients suitable for preparing compositions of the invention include, for example, potato concentrate, soy concentrate, soybean meal, soy protein isolate, com gluten meal, rice protein isolate, pea protein concentrate, wheat protein concentrate, and wheat protein isolate.
- Creatinine levels in an animal may be measured by any method known by those of skill in the art.
- the compositions of the present invention e.g., compositions to treat or prevent CKD. may also be suitable to lower the creatinine serum levels in an animal.
- the animal is a companion animal, e.g., a feline.
- the methods of the present invention, e.g., to treat or prevent CKD may be suitable to lower the creatinine serum levels in an animal.
- an effective amount is fed to the animal.
- An effective amount refer to that amount of a compound, material or composition as described herein that may be effective to achieve a particular biological result. Such results may include, but are not limited to, the treatment and/or prevention of CKD.
- An effective amount may be based on several factors, including an animal's ideal weight, the metabolizable energy of the composition, and frequency of feeding the animal compositions of the present invention, e.g., once, twice, or three times daily, and other compositions fed to the animal.
- Example 1 illustrates the effect of the compositions of the invention on preventing CKD in healthy cats.
- 0073 Food A is formulated as a dry cat food meeting the AAFCO ' s minimum nutrient level requirements for maintenance for cats. It contains soybean meal, corn gluten meal, poultry meal, and pork meat protein isolate as protein ingredients. Food A contains approximately 34% total protein on a dry matter basis; 97% of the protein was from vegetable and 3% from animal. Food A also contains 0.61 % phosphorous, and 0.35% sodium.
- Food B l is formulated as a dry cat food meeting AAFCO-S minimum nutrient level requirements for maintenance for cats. It contains soybean meal, corn gluten meal, poultry meal, and pork meat protein isolate as protein ingredients. Food B l contains approximately 34% total protein on a dry matter basis 1 , 77% of the protein was from vegetable. Food B 1 also contains 0.60% phosphorous, and 0.33% sodium.
- Food B2 is formulated as a wet cat food meeting AAFCO ' s minimum nutrient level requirements for maintenance for cats. It contains soybean meal, corn gluten meal, pork lungs, chicken, and pork liver as protein ingredients. Food B2 contains approximately 34% total protein on a dry matter basis; 32% of the protein was from vegetable. Food B2 also contains 0.60% phosphorous, and 0.30% sodium.
- Food C is formulated as a dry cat food meeting AAFCO's minimum nutrient level requirements for maintenance for cats. It contains corn gluten meal, poultry meal, and pork meat protein isolate as protein ingredients. Food C contains approximately 34% total protein on a dry matter basis; 85% of the protein was from vegetable. Food C also contains 0.62% phosphorous, and 0.35% sodium.
- Example 2 illustrates the effect of the compositions of the invention on treating CKD in cats with renal insufficiency and age matched normal cats.
- Feeding food D reduced serum creatinine levels in both the healthy cats and the cats with CKD. In addition, feeding food D also resulted in reduction in serum phosphorus level in both the healthy cats and the cats with CKD (phosphorus levels of approximately 3 Io approximately 5.6 mg/dL are considered normal).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008551549A JP2009523827A (en) | 2006-01-19 | 2007-01-19 | Compositions and methods for preventing or treating feline chronic kidney disease |
BRPI0706679-1A BRPI0706679A2 (en) | 2006-01-19 | 2007-01-19 | suitable methods and kits for preventing and treating chronic kidney disease in a feline, composition, means for communicating information, use of a composition, e.g. Method to Decrease Creatinine Serum Level in an Animal |
CA2636039A CA2636039C (en) | 2006-01-19 | 2007-01-19 | Compositions and methods for preventing or treating feline chronic kidney disease |
EP07717323.5A EP1981354B1 (en) | 2006-01-19 | 2007-01-19 | Compositions and methods for preventing feline chronic kidney disease |
AU2007205825A AU2007205825B2 (en) | 2006-01-19 | 2007-01-19 | Compositions and methods for preventing or treating feline chronic kidney disease |
EP12158853.7A EP2462815B1 (en) | 2006-01-19 | 2007-01-19 | Compositions and methods for treating feline chronic kidney disease |
US12/161,583 US20090275505A1 (en) | 2006-01-19 | 2007-01-19 | Compositions and Methods For Preventing or Treating Feline Chronic Renal Failure |
ZA2008/05958A ZA200805958B (en) | 2006-01-19 | 2008-07-08 | Compositions and methods for preventing or treating feline chronic kidney disease |
AU2011201233A AU2011201233B2 (en) | 2006-01-19 | 2011-03-18 | Compositions and methods for preventing or treating feline chronic kidney disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76006806P | 2006-01-19 | 2006-01-19 | |
US60/760,068 | 2006-01-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007084986A2 true WO2007084986A2 (en) | 2007-07-26 |
WO2007084986A3 WO2007084986A3 (en) | 2007-11-22 |
Family
ID=38163311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/060773 WO2007084986A2 (en) | 2006-01-19 | 2007-01-19 | Compositions and methods for preventing or treating feline chronic kidney disease |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090275505A1 (en) |
EP (2) | EP1981354B1 (en) |
JP (1) | JP2009523827A (en) |
CN (1) | CN101374421A (en) |
AU (2) | AU2007205825B2 (en) |
BR (1) | BRPI0706679A2 (en) |
CA (1) | CA2636039C (en) |
RU (1) | RU2404684C2 (en) |
WO (1) | WO2007084986A2 (en) |
ZA (1) | ZA200805958B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007133726A1 (en) * | 2006-05-12 | 2007-11-22 | Hill's Pet Nutrition, Inc. | Compositions and methods for preventing or treating chronic renal failure in felines with hyperthyroidism |
US8501223B2 (en) | 2003-06-20 | 2013-08-06 | Hill's Pet Nutrition, Inc. | Methods for dietary management of cats to avoid hyperthyroidism |
WO2014136035A1 (en) | 2013-03-04 | 2014-09-12 | Virbac | Nutritional and medicinal oral composition for veterinary use |
WO2014136036A1 (en) | 2013-03-04 | 2014-09-12 | Virbac | Nutritional and medicinal oral composition for veterinary use |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1986508B1 (en) * | 2006-01-26 | 2014-05-21 | Hill's Pet Nutrition, Inc. | Methods and compositions for treating feline hyperthyroidism |
BRPI0713634A2 (en) * | 2006-07-03 | 2012-10-23 | Hills Pet Nutrition Inc | use of iodine or selenium, composition and kit to prevent and / or treat cardiovascular disease in a feline with hyperthyroidism, and means to communicate information |
EP2493467B1 (en) | 2009-12-29 | 2017-05-31 | Hill's Pet Nutrition, Inc. | Compositions including pyruvate for companion animals |
WO2014092158A1 (en) * | 2012-12-13 | 2014-06-19 | ユニ・チャーム株式会社 | Pet food |
NZ711956A (en) | 2013-03-08 | 2018-06-29 | Axiom Foods Inc | Rice protein supplements |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
CN105705029B (en) | 2013-11-05 | 2020-03-03 | 希尔氏宠物营养品公司 | Palatability enhancers for foods designed for dogs and cats with renal insufficiency |
JPWO2016152706A1 (en) * | 2015-03-20 | 2017-12-28 | 株式会社明治 | Kidney function improving agent |
WO2018209131A1 (en) | 2017-05-12 | 2018-11-15 | Axiom Foods, Inc. | Rice products and systems and methods for making thereof |
KR20210120091A (en) * | 2019-02-01 | 2021-10-06 | 마아즈, 인코오포레이티드 | Feline feed composition |
CN110870512A (en) * | 2019-04-10 | 2020-03-10 | 张璐 | Diet formula for cats suffering from chronic kidney diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6039952A (en) | 1997-10-22 | 2000-03-21 | The Iams Company | Composition and method for improving clinical signs in animals with renal disease |
US20050064016A1 (en) | 2003-06-20 | 2005-03-24 | Wedekind Karen J. | Methods for dietary management of cats to avoid hyperthyroidism |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04210639A (en) * | 1990-11-30 | 1992-07-31 | Dainippon Pharmaceut Co Ltd | Dietary fiber with reduced electrolyte content |
JPH06197715A (en) * | 1992-03-16 | 1994-07-19 | Kissei Pharmaceut Co Ltd | Buckwheat noodle having adjusted protein |
JPH11243879A (en) * | 1998-03-04 | 1999-09-14 | Honke Matsuura Shuzojo:Kk | Production of rice having low phosphorus content and rice having low phosphorus content, low protein content and low potassium content and obtained thereby |
ES2203245T3 (en) * | 1998-09-02 | 2004-04-01 | Heska Corporation | METHOD AND COMPOSITION TO PROTECT A MANDATORY CARNIVOR FROM AN ABNORMAL METABOLISM DISEASE OF CARBOHYDRATES. |
JP2002204668A (en) * | 2001-01-11 | 2002-07-23 | Q P Corp | Nutritive composition |
JP2003334009A (en) * | 2002-05-20 | 2003-11-25 | Kissei Pharmaceut Co Ltd | Rice-cake-like food with adjusted component |
MXPA05013007A (en) * | 2003-06-20 | 2006-03-02 | Hills Pet Nutrition Inc | Methods for hyperthyroidism in a cat and composition comprising limited iodine. |
CA2650845C (en) * | 2006-05-12 | 2015-07-07 | Hill's Pet Nutrition, Inc. | Compositions and methods for preventing or treating chronic renal failure in felines with hyperthyroidism |
-
2007
- 2007-01-19 EP EP07717323.5A patent/EP1981354B1/en active Active
- 2007-01-19 RU RU2008133986/13A patent/RU2404684C2/en not_active IP Right Cessation
- 2007-01-19 EP EP12158853.7A patent/EP2462815B1/en active Active
- 2007-01-19 WO PCT/US2007/060773 patent/WO2007084986A2/en active Application Filing
- 2007-01-19 US US12/161,583 patent/US20090275505A1/en not_active Abandoned
- 2007-01-19 AU AU2007205825A patent/AU2007205825B2/en not_active Ceased
- 2007-01-19 CN CNA2007800032392A patent/CN101374421A/en active Pending
- 2007-01-19 JP JP2008551549A patent/JP2009523827A/en active Pending
- 2007-01-19 BR BRPI0706679-1A patent/BRPI0706679A2/en not_active IP Right Cessation
- 2007-01-19 CA CA2636039A patent/CA2636039C/en not_active Expired - Fee Related
-
2008
- 2008-07-08 ZA ZA2008/05958A patent/ZA200805958B/en unknown
-
2011
- 2011-03-18 AU AU2011201233A patent/AU2011201233B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6039952A (en) | 1997-10-22 | 2000-03-21 | The Iams Company | Composition and method for improving clinical signs in animals with renal disease |
US20050064016A1 (en) | 2003-06-20 | 2005-03-24 | Wedekind Karen J. | Methods for dietary management of cats to avoid hyperthyroidism |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS, AMI PRODUCTS - INGREDIENTS, 24 June 2004 (2004-06-24), Retrieved from the Internet <URL:http://web.archive.org/web/20030624115116/http://ami.aminews.net/en ingredienti.htm 1> |
ANONYMOUS, BENEVO VEGETARIAN CAT FOOD, 10 September 2005 (2005-09-10), Retrieved from the Internet <URL:http://web.archive.org/web/20050910051942/http://www.veggiepets.com/ actatalog/benevo_vegetarian_cat_food.html> |
BROOKS, WENDY C, KIDNEY FAILURE: WHERE TO BEGIN, 1 January 2001 (2001-01-01), Retrieved from the Internet <URL:htt://www.veterinary partner.com/Content.plx?P=A&S=0&C=0&A=572> |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501223B2 (en) | 2003-06-20 | 2013-08-06 | Hill's Pet Nutrition, Inc. | Methods for dietary management of cats to avoid hyperthyroidism |
WO2007133726A1 (en) * | 2006-05-12 | 2007-11-22 | Hill's Pet Nutrition, Inc. | Compositions and methods for preventing or treating chronic renal failure in felines with hyperthyroidism |
WO2014136035A1 (en) | 2013-03-04 | 2014-09-12 | Virbac | Nutritional and medicinal oral composition for veterinary use |
WO2014136036A1 (en) | 2013-03-04 | 2014-09-12 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US20160038420A1 (en) * | 2013-03-04 | 2016-02-11 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US10166186B2 (en) * | 2013-03-04 | 2019-01-01 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US20190083401A1 (en) * | 2013-03-04 | 2019-03-21 | Virbac | Nutritional and medicinal oral composition for veterinary use |
US10493032B2 (en) | 2013-03-04 | 2019-12-03 | Virbac | Nutritional and medicinal oral composition for veterinary use |
Also Published As
Publication number | Publication date |
---|---|
EP2462815B1 (en) | 2020-11-11 |
EP2462815A1 (en) | 2012-06-13 |
CA2636039C (en) | 2013-03-19 |
WO2007084986A3 (en) | 2007-11-22 |
BRPI0706679A2 (en) | 2011-04-05 |
CN101374421A (en) | 2009-02-25 |
AU2011201233B2 (en) | 2011-08-04 |
EP1981354B1 (en) | 2017-11-15 |
RU2008133986A (en) | 2010-02-27 |
AU2007205825A1 (en) | 2007-07-26 |
US20090275505A1 (en) | 2009-11-05 |
EP1981354A2 (en) | 2008-10-22 |
CA2636039A1 (en) | 2007-07-26 |
RU2404684C2 (en) | 2010-11-27 |
JP2009523827A (en) | 2009-06-25 |
AU2007205825B2 (en) | 2011-05-26 |
AU2011201233A1 (en) | 2011-04-07 |
ZA200805958B (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2636039C (en) | Compositions and methods for preventing or treating feline chronic kidney disease | |
EP1838166B1 (en) | Compositions and methods for improving kidney function | |
RU2411746C2 (en) | Composition (versions) and method (versions) of prevention or treatment of chronic renal insuffuciency in felidae with hyperthyroidism | |
AU2006263651B2 (en) | Methods and compositions for the prevention and treatment of kidney disease | |
CN101198259B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
WO2007022344A2 (en) | Methods and compositions for the preventioin and treatment of kidney disease | |
DK2666366T3 (en) | METHODS AND COMPOSITIONS FOR TREATING FELIN HYPERTHYROIDISM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007205825 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2636039 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2007205825 Country of ref document: AU Date of ref document: 20070119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780003239.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008551549 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2007717323 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007717323 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008133986 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12161583 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0706679 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080721 |